Research News and Research

RSS

New topical drug may help treat diabetic eye disease

Early-stage human clinical trials showed that a new topical drug was safe and had biological effects in a type of diabetic eye disease, and may offer researchers a new approach to prevent and treat diabetic macular edema.

26 Mar 2010

New experiments may hold clues for controlling cancer

A protein discovered in fruit fly eyes has brought a Johns Hopkins team closer to understanding how the human heart and other organs automatically "right size" themselves, a piece of information that may hold clues to controlling cancer.

26 Mar 2010

New study questions effectiveness of national Silver Alert program

A group of Miami University researchers studying the national Silver Alert program for locating missing adults with dementia or other cognitive impairments question the program's effectiveness and safety, given the speed in which it's being implemented throughout the country.

26 Mar 2010

Researcher extracts natural scaffold for tissue growth

It frequently happens in science that what you throw away turns out to be most valuable. It happened to Deepak Nagrath, but not for long.

26 Mar 2010

Traversa Therapeutics, sanofi-aventis sign agreement for development of PTD-DRBD RNAi delivery technology

Traversa Therapeutics announced today the signing of a research agreement with sanofi-aventis for the validation and development of Traversa’s RNAi delivery technology: PTD-DRBD. Under the agreement, the companies will study short interfering RNA (siRNA) complexed to PTD-DRBD, with the ultimate goal of developing drugs using this technology.

26 Mar 2010

Oramed Pharmaceuticals completes Phase 2b study of ORMD-0801 oral insulin capsule

Oramed Pharmaceuticals Inc. announced today the completion of its' pivotal Phase 2b clinical study of its oral insulin capsule, ORMD-0801. The Company expects to report results from this study within the coming weeks.

26 Mar 2010

Targeting Wnt/beta-catenin pathway may prevent growth and development of AML: Study

About 40 percent of children and up to 70 percent of adults in remission from acute myelogenous leukemia will have a relapse. In recent years, doctors have come to believe that this is due to leukemia stem cells, endlessly replicating cancer cells that generate the immature blood cells characteristic of leukemia and are resistant to typical cancer treatments.

26 Mar 2010

Lay health workers can help reduce childhood mortality

Lay persons in many countries who are given special training to promote or carry out some health care services may reduce childhood mortality.

26 Mar 2010

Early screening for diabetes and kidney disease can improve health outcomes

Millions of Americans may have chronic kidney disease (CKD) and not know it, according to a study appearing in an upcoming issue of the Clinical Journal of the American Society Nephrology (CJASN).

26 Mar 2010

New report urges government to ban smoking in cars to limit children's exposure to passive smoke

A new report released by the Tobacco Advisory Group of the Royal College of Physicians urges the government to ban smoking in cars and other public vehicles to limit children's exposure to passive smoke.

26 Mar 2010

SMA Foundation completes biomarker study for Spinal Muscular Atrophy

The Spinal Muscular Atrophy (SMA) Foundation, a nonprofit organization dedicated to accelerating the development of a treatment for SMA, is pleased to announce the completion of a pilot study to identify Biomarkers for Spinal Muscular Atrophy (BforSMA) and the discovery of over 400 candidate biomarkers.

26 Mar 2010

Interim results from ZALBIN Phase 2B trial in chronic hepatitis C patients announced

Human Genome Sciences, Inc. today announced interim results through Week 12 following the end of treatment in a Phase 2b clinical trial conducted by Novartis to evaluate the safety and efficacy of ZALBIN™ (albinterferon alfa-2b), an investigational agent, administered monthly in combination with ribavirin in 391 treatment-naive patients with genotypes 2 and 3 chronic hepatitis C virus. The primary efficacy endpoint is sustained virologic response (SVR) at Week 48 (24 weeks following the end of treatment).

26 Mar 2010

Artist and scientist examine principles of visual perception

A novel research project spearheaded by the University of Leicester and part-funded by The Leverhulme Trust aims to shed new light on the way people perceive art.

26 Mar 2010

Renowned experts discuss key statistics of health care reform at 2010 Keenan Summit

Keenan & Associates, the largest privately-held insurance brokerage and consulting firm in California, convened its sixth annual Keenan Summit on March 3, 2010, in Pasadena, Calif., and on March 4, 2010, in Berkeley. The theme for this year's summit was "Navigating Through Unprecedented Times: Today's Challenges. Tomorrow's Solutions."

26 Mar 2010

Dyax to use proceeds of public offering for commercialization and distribution activities of KALBITOR

Dyax Corp. today announced the pricing of an underwritten public offering of 17,000,000 shares of its common stock at a price to the public of $3.25 per share. The gross proceeds from the sale of shares, after underwriting discounts and commissions and estimated offering expenses, are expected to be approximately $51.8 million. The offering is expected to close on or about March 30, 2010, subject to customary closing conditions.

26 Mar 2010

Positive results from Stage A pivotal study of 2009 A/H1N1 VLP pandemic influenza vaccine

Novavax, Inc. announced today positive results from the entire 1,000 subject Stage A of its two-stage pivotal study evaluating the safety and immunogenicity of Novavax's unadjuvanted 2009 A/H1N1 virus-like particle pandemic influenza vaccine.

26 Mar 2010

Santarus enrolls 510 patients in Phase III clinical program for budesonide MMX

Santarus, Inc., a specialty biopharmaceutical company, today announced the completion of enrollment of 510 patients in a U.S. Phase III clinical study to evaluate budesonide MMX® administered over eight weeks for the induction of remission of mild or moderate active ulcerative colitis. This is the second Phase III clinical study being conducted in collaboration with Cosmo Technologies Ltd., a subsidiary of Cosmo Pharmaceuticals SpA, as part of the budesonide MMX Phase III clinical program for U.S. registration.

26 Mar 2010

New research may help advance treatment strategies for common liver disease

A research article published in the journal PloS Pathogens could lead to improvements in the production of vaccines for hepatitis A, the most widespread viral disease in the world.

26 Mar 2010

Leap Medical secures seed financing to develop innovative technology for detection of brain injuries

Leap Medical Inc., a privately held Medical Device company, announced today that it has successfully secured seed financing in the amount of $1.025 million (Canadian dollars) to develop its innovative technology for the rapid detection of brain injuries and infection.

26 Mar 2010

Widely-used screening scale misidentifies borderline personality disorder as bipolar disorder

A study from Rhode Island Hospital has shown that a widely-used screening tool for bipolar disorder may incorrectly indicate borderline personality disorder rather than bipolar disorder.

26 Mar 2010

Research News and Research

New topical drug may help treat diabetic eye disease

New experiments may hold clues for controlling cancer

New study questions effectiveness of national Silver Alert program

Researcher extracts natural scaffold for tissue growth

Traversa Therapeutics, sanofi-aventis sign agreement for development of PTD-DRBD RNAi delivery technology

Oramed Pharmaceuticals completes Phase 2b study of ORMD-0801 oral insulin capsule

Targeting Wnt/beta-catenin pathway may prevent growth and development of AML: Study

Lay health workers can help reduce childhood mortality

Early screening for diabetes and kidney disease can improve health outcomes

New report urges government to ban smoking in cars to limit children's exposure to passive smoke

SMA Foundation completes biomarker study for Spinal Muscular Atrophy

Interim results from ZALBIN Phase 2B trial in chronic hepatitis C patients announced

Artist and scientist examine principles of visual perception

Renowned experts discuss key statistics of health care reform at 2010 Keenan Summit

Dyax to use proceeds of public offering for commercialization and distribution activities of KALBITOR

Positive results from Stage A pivotal study of 2009 A/H1N1 VLP pandemic influenza vaccine

Santarus enrolls 510 patients in Phase III clinical program for budesonide MMX

New research may help advance treatment strategies for common liver disease

Leap Medical secures seed financing to develop innovative technology for detection of brain injuries

Widely-used screening scale misidentifies borderline personality disorder as bipolar disorder

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest Life Science News